Revolutionizing Solid Tumor Care by Applying Haematology‑Driven Insights to Optimize Clinical Delivery and Dosing
- Extracting key lessons from haematology’s shift in delivery models, including the transition from traditional IV regimens to streamlined subcutaneous approaches, and understanding how these changes have improved patient experience, clinic efficiency, and therapeutic consistency
- Leveraging haematology’s established frameworks for step‑up dosing, toxicity mitigation, and response monitoring, exploring how these principles can be adapted to solid tumor therapies to improve safety, manage CRS and related immune toxicities, and support broader outpatient administration
- Examining real‑world evidence and clinical learnings from haematology agents such as bispecifics and T‑cell engagers, and assessing how these insights are shaping the clinical deployment, exposure management, and dose optimization of emerging solid‑tumor agents, highlighting Tarlatamab and next‑generation molecules as examples of iterative improvement driving enhanced patient outcomes